NovoEight (Novo Nordisk) is a B-domain deleted recombinant factor VIII (rfVIII) therapy developed for the treatment of adult and pediatric patients with hemophilia A. Manufactured without the use of human- or animal-derived proteins, the product became Novo Nordisk’s first therapy approved for the broader hemophilia A population in 2013. Novo Nordisk had previously focused on the inhibitor population through its development of NovoSeven (rfVIIa).
NovoEight is indicated for on-demand, prophylactic, and perioperative use in both adults and children. Unlike other recent product approvals, NovoEight’s pharmacokinetic profile does not allow for a longer duration of action and less frequent prophylactic dosing. Instead, Novo Nordisk is developing the successor therapy N8-GP (glycoPEGylated rfVIII) to complement NovoEight in this way.
Pharma Intelligence UK Limited is a company registered in England and Wales with company number 13787459 whose registered office is Suite 1, 3rd Floor, 11 - 12 St. James's Square, London, England, SW1Y 4LB. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.